Free Trial
NASDAQ:GOSS

Gossamer Bio (GOSS) Stock Price, News & Analysis

Gossamer Bio logo
$0.70 +0.03 (+4.51%)
(As of 11/22/2024 ET)

About Gossamer Bio Stock (NASDAQ:GOSS)

Key Stats

Today's Range
$0.67
$0.71
50-Day Range
$0.66
$1.07
52-Week Range
$0.50
$1.60
Volume
1.79 million shs
Average Volume
903,813 shs
Market Capitalization
$157.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.20
Consensus Rating
Buy

Company Overview

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
84th Percentile Overall Score

GOSS MarketRank™: 

Gossamer Bio scored higher than 84% of companies evaluated by MarketBeat, and ranked 166th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Gossamer Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Gossamer Bio has only been the subject of 1 research reports in the past 90 days.

  • Read more about Gossamer Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Gossamer Bio are expected to decrease in the coming year, from ($0.28) to ($0.69) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gossamer Bio is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gossamer Bio is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Gossamer Bio has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Gossamer Bio's valuation and earnings.
  • Percentage of Shares Shorted

    2.78% of the outstanding shares of Gossamer Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Gossamer Bio has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Gossamer Bio has recently decreased by 9.35%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Gossamer Bio does not currently pay a dividend.

  • Dividend Growth

    Gossamer Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.78% of the outstanding shares of Gossamer Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Gossamer Bio has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Gossamer Bio has recently decreased by 9.35%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Gossamer Bio has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • Search Interest

    9 people have searched for GOSS on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Gossamer Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.00% of the stock of Gossamer Bio is held by insiders.

  • Percentage Held by Institutions

    81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Gossamer Bio's insider trading history.
Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Stock News Headlines

Gossamer Bio FY2024 EPS Estimate Raised by Leerink Partnrs
[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Gossamer Bio (GOSS) Gets a Buy from Oppenheimer
See More Headlines

GOSS Stock Analysis - Frequently Asked Questions

Gossamer Bio's stock was trading at $0.9125 on January 1st, 2024. Since then, GOSS shares have decreased by 23.8% and is now trading at $0.6956.
View the best growth stocks for 2024 here
.

Gossamer Bio, Inc. (NASDAQ:GOSS) released its quarterly earnings data on Thursday, November, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The business earned $9.48 million during the quarter, compared to the consensus estimate of $4.52 million.

Gossamer Bio (GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

Top institutional investors of Gossamer Bio include Geode Capital Management LLC (0.98%), Jacobs Levy Equity Management Inc. (0.83%), Charles Schwab Investment Management Inc. (0.54%) and The Manufacturers Life Insurance Company (0.17%). Insiders that own company stock include Faheem Hasnain, Richard Aranda, Bryan Giraudo, Laura Carter and Caryn Peterson.
View institutional ownership trends
.

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
11/07/2024
Today
11/24/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/04/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.20
High Stock Price Target
$15.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,222.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-179,820,000.00
Pretax Margin
-64.89%

Debt

Sales & Book Value

Annual Sales
$105.32 million
Book Value
$0.24 per share

Miscellaneous

Free Float
215,274,000
Market Cap
$157.63 million
Optionable
Optionable
Beta
1.96
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:GOSS) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners